Focus Partners Advisor Solutions LLC Buys New Position in Biogen Inc. $BIIB

Focus Partners Advisor Solutions LLC purchased a new position in shares of Biogen Inc. (NASDAQ:BIIB) in the 2nd quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor purchased 7,689 shares of the biotechnology company’s stock, valued at approximately $1,661,000.

A number of other institutional investors and hedge funds have also bought and sold shares of the stock. Rothschild Investment LLC grew its stake in shares of Biogen by 12.3% in the 4th quarter. Rothschild Investment LLC now owns 513 shares of the biotechnology company’s stock worth $90,000 after acquiring an additional 56 shares in the last quarter. Meeder Advisory Services Inc. lifted its position in shares of Biogen by 1.2% during the first quarter. Meeder Advisory Services Inc. now owns 4,721 shares of the biotechnology company’s stock valued at $866,000 after purchasing an additional 57 shares in the last quarter. Kera Capital Partners Inc. lifted its position in shares of Biogen by 3.5% during the first quarter. Kera Capital Partners Inc. now owns 1,723 shares of the biotechnology company’s stock valued at $316,000 after purchasing an additional 58 shares in the last quarter. Parallel Advisors LLC boosted its holdings in Biogen by 1.5% during the first quarter. Parallel Advisors LLC now owns 4,367 shares of the biotechnology company’s stock worth $801,000 after purchasing an additional 65 shares during the last quarter. Finally, Itau Unibanco Holding S.A. boosted its holdings in Biogen by 24.4% during the fourth quarter. Itau Unibanco Holding S.A. now owns 337 shares of the biotechnology company’s stock worth $59,000 after purchasing an additional 66 shares during the last quarter. 87.93% of the stock is owned by hedge funds and other institutional investors.

Wall Street Analysts Forecast Growth

Several research firms have commented on BIIB. Needham & Company LLC increased their price objective on shares of Biogen from $255.00 to $256.00 and gave the company a “buy” rating in a research note on Monday, June 29th. Morgan Stanley boosted their target price on Biogen from $222.00 to $231.00 and gave the stock an “equal weight” rating in a research note on Thursday, July 30th. Canaccord Genuity Group increased their price target on Biogen from $245.00 to $248.00 and gave the company a “buy” rating in a research report on Thursday, July 30th. Oppenheimer reiterated an “outperform” rating and set a $300.00 price target on shares of Biogen in a report on Wednesday, July 29th. Finally, Citigroup boosted their price objective on Biogen from $200.00 to $215.00 and gave the stock a “neutral” rating in a research report on Monday, August 3rd. One investment analyst has rated the stock with a Strong Buy rating, eighteen have assigned a Buy rating, thirteen have assigned a Hold rating and one has issued a Sell rating to the company’s stock. According to data from MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and an average price target of $227.07.

Biogen Trading Down 0.4%

NASDAQ:BIIB opened at $209.83 on Friday. Biogen Inc. has a 12 month low of $131.52 and a 12 month high of $219.72. The company has a current ratio of 1.87, a quick ratio of 1.26 and a debt-to-equity ratio of 0.39. The firm’s 50 day moving average is $203.76 and its 200 day moving average is $193.10. The stock has a market capitalization of $31.00 billion, a PE ratio of 37.14, a price-to-earnings-growth ratio of 6.48 and a beta of 0.17.

Biogen (NASDAQ:BIIB) last announced its quarterly earnings data on Wednesday, July 29th. The biotechnology company reported $3.60 earnings per share for the quarter, beating the consensus estimate of $2.94 by $0.66. Biogen had a return on equity of 11.18% and a net margin of 8.32%.The business had revenue of $2.74 billion during the quarter, compared to analyst estimates of $2.46 billion. During the same period in the prior year, the company earned $5.47 earnings per share. Biogen’s revenue was up 3.4% compared to the same quarter last year. Biogen has set its FY 2026 guidance at 12.000-13.000 EPS. Sell-side analysts expect that Biogen Inc. will post 12.5 earnings per share for the current year.

About Biogen

Biogen Inc is a multinational biotechnology company focused on discovering, developing and delivering therapies for neurological and neurodegenerative diseases. Headquartered in Cambridge, Massachusetts, the company has a longstanding emphasis on neuroscience, with research and commercial activities spanning multiple therapeutic areas including multiple sclerosis, spinal muscular atrophy and Alzheimer’s disease. Biogen was founded in 1978 and has grown into a global biopharmaceutical firm with operations and commercial presence across North America, Europe, Japan and other international markets.

The company’s marketed portfolio has historically included several well-known therapies for multiple sclerosis such as Avonex, Tysabri and Tecfidera, and it has pursued treatments for rare neurological conditions and genetic neuromuscular disorders.